LENZ Therapeutics, Inc. (LENZ) Dividend History

LENZ Therapeutics, Inc. (LENZ) is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders. The company specializes in designing targeted therapies that address unmet medical needs, leveraging cutting-edge research and technology to improve patient outcomes in areas such as neurodegenerative diseases and mental health conditions.

445 Marine View Ave Suite 320, Del Mar, CA, 92014
Phone: 858-925-7000
Website: https://www.lenz-tx.com

Dividend History

LENZ Therapeutics, Inc. currently does not pay dividends

Company News

  • Lenz (LENZ) Q2 Revenue Jumps 604%

    Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.

    The Motley Fool
  • LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

    Capstone data from Phase 3 CLARITY study to be presented

    GlobeNewswire Inc.
  • Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

    Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity.  Citi analyst writes that with promising Phase 3 ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: ABBV
Page data last updated 08/19/2025 17:04:18 UTC